GlassScriptPhysician profile
Asfi Rafiuddin
NPI 1801200019
$6,238.65
in general payments reported to CMS, 2019-2025
22 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,153 · 2020: $132 · 2021: $888 · 2022: $1,096 · 2023: $604 · 2024: $821 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Education: $5.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.82 |
| Education | $5.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $2,147.11 | 2019-2024 | |
| Sk Life Science, INC. | $1,047.61 | 2020-2025 | Xcopri |
| Ucb, INC. | $1,012.86 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $801.55 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $291.14 | 2022-2025 | Epidiolex |
| Eisai INC. | $166.39 | 2021-2022 | |
| Greenwich Biosciences, INC. | $165.61 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $122.70 | 2019 | |
| Pfizer INC. | $106.57 | 2023-2025 | |
| Aucta Pharmaceuticals, INC. | $96.27 | 2024-2025 | Motpoly Xr |
| Celgene Corporation | $60.00 | 2021-2022 | |
| Livanova USA, INC. | $50.32 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $29.29 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $27.98 | 2022 | |
| Biomarin Pharmaceutical INC. | $26.15 | 2024 | Brineura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $18.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Otter Pharmaceuticals, LLC | $13.76 | 2025 | Sympazan |
| Aprecia Pharmaceuticals, LLC | $13.32 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.27 | 2022 | |
| Aquestive Therapeutics, INC. | $12.90 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asfi Rafiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.